| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
2013
|
|
1 |
p. 47-47
|
artikel
|
| 2 |
A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain–Barré syndrome in Upper Egypt
|
Saad, Khaled
|
|
2016
|
|
1 |
p. 3-8
|
artikel
|
| 3 |
Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial
|
Berkovich, Regina
|
|
2017
|
|
1 |
p. 3-17
|
artikel
|
| 4 |
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
|
Havrdova, Eva
|
|
2015
|
|
1 |
p. 31-45
|
artikel
|
| 5 |
Anxiety in Parkinson’s disease: identification and management
|
Chen, Jack J.
|
|
2014
|
|
1 |
p. 52-59
|
artikel
|
| 6 |
A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS)
|
Remington, Gina M.
|
|
2010
|
|
1 |
p. 3-13
|
artikel
|
| 7 |
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis
|
Frohman, Elliot M.
|
|
2010
|
|
1 |
p. 15-28
|
artikel
|
| 8 |
Capsaicinoids in the treatment of neuropathic pain: a review
|
Peppin, John F.
|
|
2014
|
|
1 |
p. 22-32
|
artikel
|
| 9 |
Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage
|
Moussouttas, Michael
|
|
2012
|
|
1 |
p. 43-56
|
artikel
|
| 10 |
Clinical diagnosis of bilateral vestibular loss: three simple bedside tests
|
Petersen, Jens A.
|
|
2013
|
|
1 |
p. 41-45
|
artikel
|
| 11 |
Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
|
Creeke, Paul I.
|
|
2013
|
|
1 |
p. 3-17
|
artikel
|
| 12 |
Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE
|
Benešová, Yvonne
|
|
2017
|
|
1 |
p. 18-32
|
artikel
|
| 13 |
Current and future treatments for Alzheimer’s disease
|
Yiannopoulou, Konstantina G.
|
|
2013
|
|
1 |
p. 19-33
|
artikel
|
| 14 |
Daclizumab high-yield process in the treatment of relapsing–remitting multiple sclerosis
|
Preiningerova, Jana Lizrova
|
|
2017
|
|
1 |
p. 67-75
|
artikel
|
| 15 |
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
|
Bomprezzi, Roberto
|
|
2015
|
|
1 |
p. 20-30
|
artikel
|
| 16 |
Editorial
|
Gold, Ralf
|
|
2008
|
|
1 |
p. 3-3
|
artikel
|
| 17 |
Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis
|
Zettl, Uwe K.
|
|
2016
|
|
1 |
p. 9-30
|
artikel
|
| 18 |
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
|
Sellebjerg, Finn
|
|
2016
|
|
1 |
p. 31-43
|
artikel
|
| 19 |
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
|
Uitdehaag, Bernard
|
|
2011
|
|
1 |
p. 3-14
|
artikel
|
| 20 |
Nonmotor outcomes in Parkinson’s disease: is deep brain stimulation better than dopamine replacement therapy?
|
Borgohain, Rupam
|
|
2012
|
|
1 |
p. 23-41
|
artikel
|
| 21 |
Occipital nerve stimulation in primary headache syndromes
|
Lambru, Giorgio
|
|
2012
|
|
1 |
p. 57-67
|
artikel
|
| 22 |
Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE
|
Newsome, Scott D.
|
|
2017
|
|
1 |
p. 41-50
|
artikel
|
| 23 |
Plasma exchange as a cost-effective option for treating Guillain–Barré syndrome
|
Buenz, Eric J
|
|
2017
|
|
1 |
p. 76-77
|
artikel
|
| 24 |
Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab
|
Magira, Eleni E.
|
|
2016
|
|
1 |
p. 69-73
|
artikel
|
| 25 |
Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy
|
Hoepner, Robert
|
|
2014
|
|
1 |
p. 3-6
|
artikel
|
| 26 |
Reliability and validity of the Attributional Style Questionnaire- Survey in people with multiple sclerosis
|
Kneebone, Ian I.
|
|
2017
|
|
1 |
p. 33-40
|
artikel
|
| 27 |
Review: Diagnosis and treatment of cerebral vasculitis
|
Berlit, Peter
|
|
2010
|
|
1 |
p. 29-42
|
artikel
|
| 28 |
Review: Discordant findings in color-coded duplex-sonography and magnetic resonance angiography in symptomatic internal carotid artery stenosis: implications for diagnostic work-up and early intervention
|
Eyding, Jens
|
|
2010
|
|
1 |
p. 69-71
|
artikel
|
| 29 |
Review: Innovative monoclonal antibody therapies in multiple sclerosis
|
Linker, Ralf A.
|
|
2008
|
|
1 |
p. 33-42
|
artikel
|
| 30 |
Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited
|
Surges, Rainer
|
|
2008
|
|
1 |
p. 13-24
|
artikel
|
| 31 |
Review: Myoclonic disorders: a practical approach for diagnosis and treatment
|
Kojovic, Maja
|
|
2011
|
|
1 |
p. 47-62
|
artikel
|
| 32 |
Review: Progress in the management of paraneoplastic neurological disorders
|
Sadeghian, Hamid
|
|
2010
|
|
1 |
p. 43-52
|
artikel
|
| 33 |
Review: Recent and future advances in the treatment of status epilepticus
|
Rosenow, Felix
|
|
2008
|
|
1 |
p. 25-32
|
artikel
|
| 34 |
Review: The effects of deep brain stimulation on sleep in Parkinson’s disease
|
Amara, Amy W.
|
|
2011
|
|
1 |
p. 15-24
|
artikel
|
| 35 |
Review: Treatment of dysautonomia in extrapyramidal disorders
|
Ziemssen, Tjalf
|
|
2010
|
|
1 |
p. 53-67
|
artikel
|
| 36 |
Review: Treatment of neuromyelitis optica: Current debate
|
Okamoto, Tomoko
|
|
2008
|
|
1 |
p. 43-52
|
artikel
|
| 37 |
Review: Treatment strategies for tics in Tourette syndrome
|
Eddy, Clare M.
|
|
2011
|
|
1 |
p. 25-45
|
artikel
|
| 38 |
Smoking: effects on multiple sclerosis susceptibility and disease progression
|
Wingerchuk, Dean M.
|
|
2012
|
|
1 |
p. 13-22
|
artikel
|
| 39 |
Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction
|
Hadden, Robert D. M.
|
|
2015
|
|
1 |
p. 14-19
|
artikel
|
| 40 |
Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management
|
Bittner, Stefan
|
|
2017
|
|
1 |
p. 51-66
|
artikel
|
| 41 |
Targeting heat shock proteins to modulate α-synuclein toxicity
|
Jones, Daryl Rhys
|
|
2014
|
|
1 |
p. 33-51
|
artikel
|
| 42 |
The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
|
Milo, Ron
|
|
2014
|
|
1 |
p. 7-21
|
artikel
|
| 43 |
The optimal management of headaches in children and adolescents
|
Kacperski, Joanne
|
|
2016
|
|
1 |
p. 53-68
|
artikel
|
| 44 |
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine
|
Reuter, Uwe
|
|
2015
|
|
1 |
p. 46-54
|
artikel
|
| 45 |
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects
|
Sorensen, Per Soelberg
|
|
2016
|
|
1 |
p. 44-52
|
artikel
|
| 46 |
Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model
|
Stangel, Martin
|
|
2015
|
|
1 |
p. 3-13
|
artikel
|
| 47 |
Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis
|
Rieckmann, Peter
|
|
2012
|
|
1 |
p. 3-12
|
artikel
|
| 48 |
Treatment of complex neurovascular lesions: an interdisciplinary angio suite approach
|
Dammann, Philipp
|
|
2014
|
|
1 |
p. 60-70
|
artikel
|
| 49 |
Ventricular tachycardia during basilar-type migraine attack
|
Pitarokoili, Kalliopi
|
|
2013
|
|
1 |
p. 35-40
|
artikel
|
| 50 |
What are the therapeutic advances in neurology? Opinions from world experts
|
Mallarkey, Gordon
|
|
2008
|
|
1 |
p. 5-12
|
artikel
|
Tijdschrift beschrijving